146 results
Page 3 of 8
8-K
EX-2.1
3qs0v72e
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
8-K
EX-99.2
iny7gk13z5y pc2
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
8-K
EX-99.1
rla1xe sm81l316vp1ws
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
jawelbx
29 Mar 21
Business combination disclosure
7:27am
425
EX-99.1
d477do
29 Mar 21
Business combination disclosure
7:27am
425
EX-99.2
0dgp28n 6u67wq
29 Mar 21
Business combination disclosure
7:27am
8-K
EX-99.1
tipuuo5 c1rr
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am
8-K
f0b6p
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
EX-99.1
q0mfzs
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
EX-99.1
csi oa9pe0sayy
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.2
0g36celise9wo3
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.1
hdbslgg
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
EX-1.1
093as0il97dwn14ku8
4 Mar 20
Entry into a Material Definitive Agreement
8:37am
8-K
EX-99.1
s64fg0a251uwe6v
10 Feb 20
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
8:42am